Santana Orlando, Xydas Steve, Williams Roy F, LaPietra Angelo, Mawad Maurice, Rosen Gerald P, Beohar Nirat, Mihos Christos G
The Columbia University Division of Cardiology, at the Mount Sinai Heart Institute, Miami Beach, FL, USA.
The Division of Cardiac Surgery, Mount Sinai Heart Institute, Miami Beach, FL, USA.
J Thorac Dis. 2017 Jun;9(Suppl 7):S569-S574. doi: 10.21037/jtd.2017.04.28.
In patients requiring coronary revascularization and aortic valve replacement, a combined approach of percutaneous coronary intervention followed by minimally invasive aortic valve replacement may be a viable treatment strategy.
The outcomes of 123 consecutive patients with significant coronary artery and aortic valve disease, who underwent percutaneous coronary intervention followed by elective minimally invasive aortic valve replacement between February 2009 and April 2014, were retrospectively evaluated.
The cohort consisted of 80 males and 43 females, with a mean age of 75.7±8.1 years. Drug-eluting stents were used in 69.9% of the patients, and 64.2% were on dual anti-platelet therapy at the time of aortic valve replacement. Within a median of 39 days (IQR 21-64), 83.7% of the patients underwent primary and 16.3% underwent re-operative minimally invasive aortic valve replacement. Post-operatively, there was 1 (0.8%) cerebrovascular accident, 1 patient (0.8%) required a re-operation due to bleeding, and 2 (1.6%) developed acute kidney injury. Thirty-day mortality occurred in 2 (1.6%) patients. Follow-up was available for all of the patients, and at a mean follow-up period of 14.3±12.5 months, 4 (3.3%) had an acute coronary syndrome, and 1 (0.8%) required a repeat target vessel revascularization. The actuarial survival rate at 1- and 3-year was 92.7% and 89.4%, respectively.
In a select group of patients with coronary artery and aortic valve disease, a combined approach of percutaneous coronary intervention followed by minimally invasive aortic valve replacement can be safely performed with excellent short-term and midterm outcomes.
在需要进行冠状动脉血运重建和主动脉瓣置换的患者中,先进行经皮冠状动脉介入治疗,然后进行微创主动脉瓣置换的联合治疗方法可能是一种可行的治疗策略。
回顾性评估了2009年2月至2014年4月期间连续123例患有严重冠状动脉和主动脉瓣疾病的患者的治疗结果,这些患者先接受了经皮冠状动脉介入治疗,随后接受了择期微创主动脉瓣置换。
该队列包括80名男性和43名女性,平均年龄为75.7±8.1岁。69.9%的患者使用了药物洗脱支架,64.2%的患者在进行主动脉瓣置换时接受双联抗血小板治疗。在中位时间39天(四分位间距21 - 64天)内,83.7%的患者接受了初次微创主动脉瓣置换,16.3%的患者接受了再次手术微创主动脉瓣置换。术后发生1例(0.8%)脑血管意外,1例患者(0.8%)因出血需要再次手术,2例(1.6%)发生急性肾损伤。2例(1.6%)患者发生30天死亡率。所有患者均获得随访,平均随访期为14.3±12.5个月,4例(3.3%)发生急性冠状动脉综合征,1例(0.8%)需要进行再次靶血管血运重建。1年和3年的精算生存率分别为92.7%和89.4%。
在一组特定的冠状动脉和主动脉瓣疾病患者中,先进行经皮冠状动脉介入治疗,然后进行微创主动脉瓣置换的联合治疗方法可以安全实施,并具有良好的短期和中期疗效。